Impute the Missing Data Using Retrieved Dropouts

Abstract

Background: In the past few decades various methods have been proposed to handle missing data of clinical studies, so as to assess the robustness of primary results. Some of the methods are based on the assumption of missing at random (MAR) which assumes subjects who discontinue the treatment will maintain the treatment effect after discontinuation. The agency, however, has expressed concern over methods based on this overly optimistic assumption, because it hardly holds for subjects discontinuing the investigational product (IP). Although in recent years a good number of sensitivity analyses based on missing not at random (MNAR) assumptions have been proposed, some use very conservative assumption on which it might be hard for sponsors and regulators to reach common ground.Methods: Here we propose a multiple imputation method targeting at “treatment policy” estimand based on the MNAR assumption. This method can be used as the primary analysis, in addition to serving as a sensitivity analysis. It imputes missing data using information from retrieved dropouts defined as subjects who remain in the study despite occurrence of intercurrent events. Then imputed data long with completers and retrieved dropouts are analyzed altogether and finally multiple results are summarized into a single estimate. According to definition in ICH E9 (R1), this proposed approach fully aligns with the treatment policy estimand but its assumption is much more realistic and reasonable. Results: Our approach has well controlled type I error rate with no loss of power. As expected, the effect size estimates take into account any dilution effect contributed by retrieved dropouts, conforming to the MNAR assumption.Conclusions: Although multiple imputation approaches are always used as sensitivity analyses, this multiple imputation approach can be used as primary analysis for trials with sufficient retrieved dropouts or trials designed to collect retrieved dropouts.

Identification and Validation of Immune Pathway Subtyping in Glioblastoma to Predict Clinical Prognosis and Immunotherapy Response in Patients

“…The 450K methylation data of glioma samples from the TCGA dataset were downloaded, and then to complete the missing values (24), we used the KNN algorithm of the "impute" package. Further, 7 EMT promoting genes (25) were we obtained from existing studies, and we analyzed the mean beta values of these genes across different subtypes and calculated the Pearson correlation between the gene expression values and the beta values of methylation.…”

“…To investigate the methylation of cancer driver genes, we collected 7 EMT-promoting genes (24) from an existing study, and then analyzed the differences in the mean methylation beta values of these genes in the subtypes. There were no differences in the methylation beta values of VIM, ZEB2, and CLDN1, ZEB1 among the three subtypes, while CDH1 and TWIST1, CDH2 were greatly different (Figure 6A).…”

How Risk Perception Impacts Cervical Cancer Knowledge Acquisition in China: From an Adapted Cognitive Mediation Model Perspective

“…There are about 110 thousands of cervical cancer new cases in China every year, which makes cervical cancer the second most prevalent gynecological cancer in China [1]. A sexually transmitted infection named the 'human papillomavirus (HPV)' primarily causes cervical cancer [2].…”